- Home
- DRMA vs XRTX Comparison
DRMA vs XRTX Comparison
Compare DRMA & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRMA
- XRTX
- Stock Information
- Founded
- DRMA 2014
- XRTX 2011
- Country
- DRMA United States
- XRTX Canada
- Employees
- DRMA N/A
- XRTX N/A
- Industry
- DRMA Biotechnology: Pharmaceutical Preparations
- XRTX Pharmaceuticals and Biotechnology
- Sector
- DRMA Health Care
- XRTX Health Care
- Exchange
- DRMA Nasdaq
- XRTX Nasdaq
- Market Cap
- DRMA 4.5M
- XRTX 4.2M
- IPO Year
- DRMA 2021
- XRTX N/A
- Fundamental
- Price
- DRMA $0.60
- XRTX $0.84
- Analyst Decision
- DRMA Strong Buy
- XRTX
- Analyst Count
- DRMA 1
- XRTX 0
- Target Price
- DRMA $3.00
- XRTX N/A
- AVG Volume (30 Days)
- DRMA 94.5K
- XRTX 30.3K
- Earning Date
- DRMA 08-06-2025
- XRTX 08-13-2025
- Dividend Yield
- DRMA N/A
- XRTX N/A
- EPS Growth
- DRMA N/A
- XRTX N/A
- EPS
- DRMA N/A
- XRTX N/A
- Revenue
- DRMA N/A
- XRTX N/A
- Revenue This Year
- DRMA N/A
- XRTX N/A
- Revenue Next Year
- DRMA N/A
- XRTX N/A
- P/E Ratio
- DRMA N/A
- XRTX N/A
- Revenue Growth
- DRMA N/A
- XRTX N/A
- 52 Week Low
- DRMA $0.57
- XRTX $0.80
- 52 Week High
- DRMA $5.00
- XRTX $2.98
- Technical
- Relative Strength Index (RSI)
- DRMA 29.24
- XRTX 39.98
- Support Level
- DRMA $0.57
- XRTX $0.80
- Resistance Level
- DRMA $0.63
- XRTX $0.88
- Average True Range (ATR)
- DRMA 0.04
- XRTX 0.05
- MACD
- DRMA -0.01
- XRTX -0.00
- Stochastic Oscillator
- DRMA 11.55
- XRTX 24.20
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.